Patent application number | Description | Published |
20110213021 | COMPOSITIONS AND METHODS FOR TREATING NOS-ASSOCIATED DISEASES - The disclosures herein provide lipoic acid salts, as well as polymorphs, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, or injection. Such compositions may be used to treat NOS-associated diseases such as inflammatory diseases, metabolic diseases and neurodegenerative diseases. | 09-01-2011 |
20110262976 | PRODUCTION OF R-a-LIPOIC ACID BY FERMENTATION USING GENETICALLY ENGINEERED MICROORGANISMS - This application provides systems and methods for the production of R-α-lipoic acid. Lipoic acid synthesis genes may be expressed in an acid-tolerant microorganism, such as | 10-27-2011 |
20150087660 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC DISEASES AND INFLAMMATORY DISORDERS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of chronic diseases and inflammatory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of intermittent claudication, obstructed arteries in the limbs, vascular dementia, Peyronie's disease, neuropathic injuries, sickle cell disease, nausea and headaches in the mountains (altitude sickness), acute alcoholic and non-alcoholic steatohepatitis, alcoholic liver disease, fibrotic lesions induced by radiation therapy for cancer, cytokine release syndrome, endometriosis, venous disease, inflammation, cancer, stroke, thrombosis, sepsis, gangrene, infection, type 1 diabetes, type 2 diabetes, pancreatic beta cell degeneration, beta cell dysfunction, respiratory diseases, rheumatoid arthritis, arthritis, osteoarthritis and vascular disease. | 03-26-2015 |
20150087670 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cough caused by minor throat and bronchial irritation (such as commonly accompanies the flu and common cold), as well as those resulting from inhaled particle irritants, upper respiratory infections, (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis, neuropathic pain and pain associated with fibromyalgia. | 03-26-2015 |
20150087674 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE PAIN - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of severe pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of postoperative pain, cancer pain, kidney stones pain, fractures, local pain, chronic pain, chemotherapy induced pain, neuropathic pain, post herpetic neuralgia, neuralgia, motor neurone disease, diabetic neuropathy, postherpetic neuralgia, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, cancer pain and lower back pain. | 03-26-2015 |
20150087697 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE PAIN - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing muscle pain, a neurological disease, allergy, respiratory diseases or inflammatory disorder may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of muscle disorders, muscle pain, spasticity, neuropathic pain, fibromyalgia, Parkinson's disease, allergy, chronic obstructive pulmonary disease, allergic rhinitis, headache, chronic pain, sub-chronic pain and local pain or its associated complications. | 03-26-2015 |
20150111932 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing neurological degenerative disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Parkinson's disease (PD), restless legs syndrome (RLS), cluster headache, depression, fibromyalgia, sexual dysfunction, amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and depression. | 04-23-2015 |
20150111966 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FIBROMYALGIA PAIN - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, bipolar depression, stress, cancer pain, and lower back pain. | 04-23-2015 |
20150119344 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR AND NEUROLOGICAL DISEASES - The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II or formula III and methods for the treatment of cardiovascular and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia, cardiovascular complications, postprandial hyperglycemia, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, inflammation, Crohn's disease, inflammatory bowel disease and obesity. | 04-30-2015 |
20150119409 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing inflammatory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of intermittent claudication resulting from obstructed arteries in the limbs, and vascular dementia, improves blood flow through peripheral blood vessels and therefore helps with blood circulation in the arms and legs (e.g. intermittent claudication), and the brain (hence its use in vascular dementia), venous disease, Peyronie's disease, neuropathic injuries, strokes, sickle cell disease, nausea and headaches in the mountains (altitude sickness), non-alcoholic steatohepatitis and alcoholic liver disease, fibrotic lesions induced by radiation therapy for breast cancer, cytokine release syndrome, cancer, type 1 diabetes and type 2 diabetes, asthma, bronchodilation, kidney diseases, renal protection, vascular ischemia, neuroprotection, vasodilation, Alzheimer's disease, dementia, stroke, and treatment of endometriosis. | 04-30-2015 |
20150119423 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LOCAL PAIN - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of local pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of moderate to severe pain, neuropathic pain, post herpetic neuralgia and rheumatic pains. | 04-30-2015 |
20150119452 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain. | 04-30-2015 |
20150126497 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute hypertension or malignant hypertension, hypoglycemia in disease states such as insulinoma (a tumor producing insulin) or congenital hyperinsulinism, hyperuricemia, gout, dyslipidemia, obesity, urea cycle disorders, hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia and cardiovascular complications. | 05-07-2015 |
20150126567 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAMILIAL AMYLOID POLYNEUROPATHY - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of familial amyloid polyneuropathy may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of transthyretin-related hereditary amyloidosis, neurodegenerative diseases, amyloidosis, neuropathic pain, amyloid fibril formation and cardiomyopathy related diseases. | 05-07-2015 |
20150126568 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERTENSION AND MANAGEMENT OF DIABETIC KIDNEY DISEASE - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing hypertension and diabetic kidney disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes related renal complications, hypertension, albuminuria, Heart Diseases, ESRD, Kidney GFR complications, Vascular Disease, Ventricular Septal Defect, vascular dilation, high blood pressure, congestive heart failure (CHF), post-myocardial infarction (MI). | 05-07-2015 |
20150126591 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be also used for the treatment of Huntington's disease, Alzheimer's disease, Multiple Sclerosis, Lateral Sclerosis, Neural Motor disorders. | 05-07-2015 |
20150126593 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ASTHMA AND ALLERGY - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of asthma and allergy may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of respiratory diseases, respiratory disorders, COPD, bronchitis, brain injury, inflammation, inflammatory skin diseases, asthma, allergic reactions, infections due to acute allergy, bronchospasm, respiratory distress, acute asthma, leukotrienes over activity, 5-LO enzyme activity and cancer. | 05-07-2015 |
20150133408 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESTLESS LEG SYNDROME AND FIBROMYALGIA - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia, restless leg syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of motor neurone disease, diabetic neuropathy, postherpetic neuralgia, acute opioid withdrawal management, obsessive-compulsive disorder, premature ejaculation, PTSD, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, bipolar depression, depression, stress, cancer pain and lower back pain. | 05-14-2015 |
20150133475 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERIODONTITIS AND RHEUMATOID ARTHRITIS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of periodontitis and rheumatoid arthritis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. | 05-14-2015 |
20150133533 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF COUGH - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing cough may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute respiratory tract infections, asthma, gout, fibromyalgia, facilitating conception, promotes secondary mucosal secretions in the respiratory system, muscle relaxant, allergy, asthma, chronic obstructive pulmonary disorders, spasms, respiratory and neurological diseases. | 05-14-2015 |
20150141384 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing neurological degenerative disorders, may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Alzheimer's disease, Lewy body disease, Huntington's disease, Amyotrophic lateral sclerosis (ALS) and Parkinson's disease. | 05-21-2015 |
20150141451 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating chronic pain in a disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute pain (such as post-operative pain), palliative care to alleviate the severe, chronic, disabling pain of terminal conditions such as cancer, and degenerative conditions such as rheumatoid arthritis, non-malignant chronic pain, chemotherapy induced pain, musculoskeletal pain, sciatica, radiculopathy pain, migraine, neuropathic pain, post herpetic neuralgia, neuralgia pain, multiple sclerosis, multiple sclerosis, restless legs syndrome (RLS), cluster headache, depression, fibromyalgia and amyotrophic lateral sclerosis (ALS). | 05-21-2015 |
20150141468 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing metabolic disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be also used to the treatment of diabetes, lipid peroxidation, hypertriglyceridemia, metabolic disorders, free radical generated due to reactive oxygen and carbonyl groups, ionizing radiation, advanced glycation end products, kidney disease, renal complications and kidney stone disease. | 05-21-2015 |
20150141479 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MODERATE TO SEVERE PAIN - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating or preventing or modulating moderate to severe pain in a disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of pain, severe pain, chronic pain, chemotherapy induced pain, epilepsy, glaucoma, arthritis, tooth aches, inflammation, musculoskeletal pain, sciatica, radiculopathy pain, migraine, neuropathic pain, post herpetic neuralgia, neuralgia pain, multiple sclerosis, multiple sclerosis, restless legs syndrome (RLS), cluster headache, depression, fibromyalgia, amyotrophic lateral sclerosis (ALS), convulsions, partial seizures, mood-stabilizing agent and bipolar disorder. | 05-21-2015 |
20150141500 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of depressive disorders, anxiety disorders, attention deficit hyperactivity disorder, migraine prophylaxis, eating disorders, bipolar disorder, post-herpetic neuralgia, insomnia, ankylosing spondylitis, recurring biliary dyskinesia, nocturnal enuresis, cyclic vomiting syndrome, post-traumatic stress disorder (PTSD) and neuropathy. | 05-21-2015 |
20150141513 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS AND NEUROLOGICAL DISEASES - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological degenerative disorders and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of narcolepsy, shift work sleep disorder, and as an adjunct treatment for obstructive sleep apnea/hypopnea, hypersomnias, like idiopathic hypersomnia, Psychiatric/neurodegenerative disorders, ADHD, Psychiatric/neurodegenerative disorders, Depersonalization disorder, Cognitive enhancement, Fatigue, Post-chemotherapy cognitive impairment and weight loss. | 05-21-2015 |
20150148306 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of inflammation may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Type II diabetes, Type I diabetes, insulin resistance, cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dyslipidemia, retinopathy, nephropathy, neuropathy, macular adema, arthritis, osteoarthritis, rheumatoid arthritis, inflammatory bowel syndrome, neudegeneration, Alzheimer's disease, Huntington's disease, Ulcerative colitis, Crohn's disease, Multiple Sclerosis, muscular dystropthy, metabolic syndrome, fatty liver, bone diseases, inflammatory diseases. | 05-28-2015 |
20150148352 | COMPOSITIONS AND METHODS FOR THE TREATMENT ANGINA AND CARDIOVASCULAR CONDITIONS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of angina and cardiovascular conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic aneurysm, angina, atherosclerosis, cerebrovascular accident (stroke), cerebrovascular disease, congestive heart failure, coronary artery disease, myocardial infarction (heart attack), peripheral vascular disease, aortic dissection, aortic stenosis, arrhythmia (irregular heartbeat), atrial fibrillation, cardiomyopathy, chest pain, claudication, congenital heart disease. | 05-28-2015 |
20150152057 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGIC DISEASES - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurologic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, migraine, neuropathic pain, post herpetic neuralgia, pain, Creutzfeld-Jakob disease, Alzheimer's disease, multiple sclerosis, Batten disease, multiple sclerosis, Parkinson's disease (PD), restless legs syndrome (RLS), cluster headache, depression, fibromyalgia, sexual dysfunction, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, autism, bipolar disorder and anxiety disorder, trigeminal neuralgia, attention-deficit hyperactivity disorder, schizophrenia, neuropathic pain, seizures, bipolar disorder and mania. | 06-04-2015 |
20150152060 | COMPOSITIONS AND METHODS FOR THE TREATMENT MIGRAINE AND NEUROLOGIC DISEASES - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of migraine and neurologic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, migraine, Post Herpetic Neuralgia, Acute and Chronic Pain, Alzheimer's disease, Creutzfeld Disease, familial amyloid polyneuropathy, parkinson's disease, fibromyalgia syndrome. | 06-04-2015 |
20150152081 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE PAIN - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of severe pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain, generalized pain disorders, leukemia, cancer, chronic pain, chemotherapy induced pain, epilepsy, migraine, neuropathic pain, post herpetic neuralgia, neuralgia, pain, drug addiction, detoxification of drugs, Alzheimer's disease, multiple sclerosis, multiple sclerosis, restless legs syndrome (RLS), cluster headache, depression, fibromyalgia, amyotrophic lateral sclerosis (ALS), convulsions, partial seizures, mood-stabilizing agent and bipolar disorder. | 06-04-2015 |
20150210667 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTONOMIC AND OTHER NEUROLOGICAL DISORDERS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of autonomic and other neurological disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurogenic orthostatic hypotension (NOH), as well as NOH associated with multiple system atrophy (MSA), familial amyloid polyneuropathy (FAP), pure autonomic failure (PAF), and Parkinson's disease (PD), intradialytic hypotension (IDH) or hemodialysis-induced hypotension, hypotension associated with fibromyalgia syndrome (FMS) and chronic fatigue syndrome (CFS). | 07-30-2015 |
20150218136 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGIC DISEASES - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurologic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of depression, Alzheimer's disease, multiple sclerosis, Batten disease, multiple sclerosis, Parkinson's disease (PD) and restless legs syndrome (RLS). | 08-06-2015 |
Patent application number | Description | Published |
20150057347 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION AND LIPID DISORDERS - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammation and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hypertriglyceridemia, steatohepatitis, cystinosis and inflammatory diseases. | 02-26-2015 |
20150080345 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. such compositions may be used to treatment of fasting hyperglycemia, diabetes mellitus type 2, impaired fasting glucose, impaired glucose tolerance, or insulin resistance, high blood pressure, central obesity (also known as visceral, male-pattern or apple-shaped adiposity), overweight with fat deposits mainly around the waist, decreased HDL cholesterol, elevated triglycerides, hyperuricemia, fatty liver (especially in concurrent obesity) progressing to NAFLD, polycystic ovarian syndrome (in women), hypophosphatemia, renal diseases, albuminuria, end stage renal disease, and acanthosis nigricans. | 03-19-2015 |
20150119409 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing inflammatory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of intermittent claudication resulting from obstructed arteries in the limbs, and vascular dementia, improves blood flow through peripheral blood vessels and therefore helps with blood circulation in the arms and legs (e.g. intermittent claudication), and the brain (hence its use in vascular dementia), venous disease, Peyronie's disease, neuropathic injuries, strokes, sickle cell disease, nausea and headaches in the mountains (altitude sickness), non-alcoholic steatohepatitis and alcoholic liver disease, fibrotic lesions induced by radiation therapy for breast cancer, cytokine release syndrome, cancer, type 1 diabetes and type 2 diabetes, asthma, bronchodilation, kidney diseases, renal protection, vascular ischemia, neuroprotection, vasodilation, Alzheimer's disease, dementia, stroke, and treatment of endometriosis. | 04-30-2015 |
20150119424 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY AND NEUROLOGICAL DISEASES - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of epilepsy and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of convulsions, Lennox-Gastaut syndrome, migraine, bipolar disorder, post traumatic stress disorder. | 04-30-2015 |
20150119436 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLOOD CLOTTING DISORDERS - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing blood clotting disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of strokes in those with atrial fibrillation due to causes other than heart valve disease, and at least one additional risk factor for stroke (congestive heart failure, hypertension, age, diabetes, and prior stroke), and to prevent the formation of blood clots in the veins in adults operated to replace a hip or knee. | 04-30-2015 |
20150133407 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of viscid or excessive mucus, cough, inflammation, redness in sore throat, infection in the throat, sore throat, abnormal mucus secretion, impaired mucus transport, allergic rhinitis, asthma, COPD, respiratory muscular disorders and pain in acute sore throat. | 05-14-2015 |
20150183728 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES - The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance. | 07-02-2015 |
20150307446 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucus diseases related to painful inflammation and ulceration of the digestive tract lining and in the mouth. | 10-29-2015 |
20150353522 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MODERATE TO SEVERE PAIN - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing moderate to severe pain, may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of muscle pain, spasticity, neuropathic pain, fibromyalgia, post-operative pain, muscle spasticity, headache, chronic pain, sub-chronic pain and local pain. | 12-10-2015 |
20160090350 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS - The invention relates to the compounds of formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and other inflammatory diseases. | 03-31-2016 |
20160090379 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY AND NEUROLOGICAL DISORDERS - The invention relates to the compounds of formula I and formula Ia or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of formula I or formula Ia; and methods for treating or preventing epilepsy, seizures and convulsions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, seizures and convulsions. | 03-31-2016 |
Patent application number | Description | Published |
20100074125 | DISCOVERING COMMUNICATION RULES IN A NETWORK TRACE - The claimed subject matter provides a system and/or a method that facilitates managing a network by mining a communication rule. An analysis engine can employ a packet trace within a network in order to provide timing information, wherein the network includes at least one of a host, a protocol, or an application. A traffic evaluator can extract a communication rule for the network based upon an activity matrix generated from the timing information in which the activity matrix includes at least one of a row of a time window for the packet trace and a column for a flow in the packet trace. | 03-25-2010 |
20110087799 | Flyways in Data Centers - Described is a technology by which additional network communications capacity is provided to an oversubscribed base network where needed, through the use of dynamically provisioned communications links referred to as flyways. A controller detects a need for additional network communications capacity between two network machines, e.g., between two racks of servers with top-of-rack switches. The controller configures flyway mechanisms (e.g., one per rack) to carry at least some of the network traffic between the machines of the racks and thereby provide the additional network communications capacity. The flyway mechanisms may be based on any wireless or wired technologies, including 60 GHz technology, optical links, 802.11n or wired commodity switches. | 04-14-2011 |
20110087924 | Diagnosing Abnormalities Without Application-Specific Knowledge - Methods, articles, and systems for determining a probable cause of a component's abnormal behavior are described. To determine the probable cause, a computing device computes, for one or more pairs of components having dependency relationships, a likelihood that behavior of one component of a pair is impacting behavior of the other component of the pair. This computing is based on joint historical behavior of the pair of components. The computing device then determines that one of a plurality of components is a probable cause of the abnormal behavior based on the computed likelihoods. | 04-14-2011 |
20110246897 | INTERACTIVE VISUALIZATION TO ENHANCE AUTOMATED FAULT DIAGNOSIS IN NETWORKS - Described is a visual analytics system for network diagnostics. The visual analytics system obtains network diagnostic-related information from a diagnostic system. The visual analytics system includes an interactive user interface that displays the representations of network components, including network machines and, zero or more links between those components, (e.g., as appropriate based upon selection or dynamic conditions). The user interface includes a main network view that displays representations of network components, a diagnostics view that displays suggested diagnosis results obtained from the diagnostic system, and a performance counter view that displays performance counter data. User interaction with one of the views correspondingly changes the displays in the other views. The system allows effective exploration of multiple levels of detail, e.g., variable, component, edge level and network levels, for example, via flexible navigation across these levels from the top, the bottom, or anywhere in the middle, while retaining context. | 10-06-2011 |
20120167101 | SYSTEM AND METHOD FOR PROACTIVE TASK SCHEDULING - The described implementations relate to distributed computing. One implementation provides a system that can include an outlier detection component that is configured to identify an outlier task from a plurality of tasks based on runtimes of the plurality of tasks. The system can also include a cause evaluation component that is configured to evaluate a cause of the outlier task. For example, the cause of the outlier task can be an amount of data processed by the outlier task, contention for resources used to execute the outlier task, or a communication link with congested bandwidth that is used by the outlier task to input or output data. The system can also include one or more processing devices configured to execute one or more of the components. | 06-28-2012 |
20120311127 | Flyway Generation in Data Centers - The subject disclosure is directed towards configuring and controlling wireless flyways (e.g., communication links between server racks provisioned on demand in a data center) to operate efficiently and without interfering with one another. Control and flyway selection may be based upon steered antenna directionality, channel, location in the data center, transmit power, and measured and/or predicted (estimated) network traffic. Flyways also may be used to route indirect traffic to reduce traffic on a bottleneck (e.g., wired) link. A payload may be sent over a over a wireless flyway with acknowledgment via a wired backchannel so that wireless communication is in one direction. The lack of interference and communication in one direction facilitates flyway operation without a backoff function and/or without clear channel assessment. | 12-06-2012 |
20130003538 | PERFORMANCE ISOLATION FOR CLOUDS - Traffic in a cloud is controlled by the nodes participating in the cloud. Tenants of the cloud each have a ratio. On any given node, a current transmission rate of the node is allocated among the tenants of the node, or more specifically, their execution units (e.g., virtual machines) on the node. Thus each tenant receives a predefined portion of the transmission capacity of the node. The transmission capacity can vary as conditions on the network change. For example, if congestion occurs, the transmission capacity may be decreased. Nonetheless, each tenant receives, according to its ratio, a same relative portion of the overall transmission capacity. | 01-03-2013 |
20130212277 | COMPUTING CLUSTER WITH LATENCY CONTROL - A computing cluster operated according to a resource allocation policy based on a predictive model of completion time. The predictive model may be applied in a resource control loop that iteratively updates resources assigned to an executing job. At each iteration, the amount of resources allocated to the job may be updated based on of the predictive model so that the job will be scheduled to complete execution at a target completion time. The target completion time may be derived from a utility function determined for the job. The utility function, in turn, may be derived from a service level agreement with service guarantees and penalties for late completion of a job. Allocating resources in this way may maximize utility for an operator of the computing cluster while minimizing disruption to other jobs that may be concurrently executing. | 08-15-2013 |
20130343191 | ENSURING PREDICTABLE AND QUANTIFIABLE NETWORKING PERFORMANCE - The ensuring of predictable and quantifiable networking performance. Embodiments of the invention combine a congestion free network core with a hypervisor based (i.e., edge-based) throttling design to help insure quantitative and invariable subscription bandwidth rates. A lightweight shim layer in a hypervisor can adaptively throttle the rate of VM-to-VM traffic flow. A receiving hypervisor can detect congestion and communicate back to sending hypervisors that rates are to be regulated. In response, sending hypervisors can reduce transmission rate to mitigate congestion at the receiving hypervisor. In some embodiments, the principles are extended to any message processors communicating over a congestion free network. | 12-26-2013 |
20130343399 | OFFLOADING VIRTUAL MACHINE FLOWS TO PHYSICAL QUEUES - The present invention extends to methods, systems, and computer program products for offloading virtual machine flows to physical queues. A computer system executes one or more virtual machines, and programs a physical network device with one or more rules that manage network traffic for the virtual machines. The computer system also programs the network device to manage network traffic using the rules. In particular, the network device is programmed to determine availability of one or more physical queues at the network device that are usable for processing network flows for the virtual machines. The network device is also programmed to identify network flows for the virtual machines, including identifying characteristics of each network flow. The network device is also programmed to, based on the characteristics of the network flows and based on the rules, assign one or more of the network flows to at least one of the physical queues. | 12-26-2013 |
20130346465 | APPLICATION ENHANCEMENT USING EDGE DATA CENTER - A management service that receives requests for the cloud computing environment to host applications, and improves performance of the application using an edge server. In response to the original request, the management service allocates the application to run on an origin data center, evaluates the application by evaluating at least one of the application properties designated by an application code author or provider, or the application performance, and uses an edge server to improve performance of the application in response to evaluating the application. For instance, a portion of application code may be offloaded to run on the edge data center, a portion of application data may be cached at the edge data center, or the edge server may add functionality to the application. | 12-26-2013 |
20130346558 | DELIVERY CONTROLLER BETWEEN CLOUD AND ENTERPRISE - A delivery controller for use in an enterprise environment that communicates with a cloud computing environment that is providing a service for the enterprise. As the cloud service processing progresses, some cloud service data is transferred from the cloud computing environment to the enterprise environment, and vice versa. The cloud service data may be exchanged over any one of a number of different types of communication channels. The delivery controller selects which communication channel to use to transfer specific data, depending on enterprise policy. Such policy might consider any business goals of the enterprise, and may be applied at the application level. | 12-26-2013 |
20130346968 | Automated controlling of host over network - The provisioning of a host computing system by a controller located over a wide area network. The host computing system has power-on code that automatically executes upon powering up, and causes the host to notify the controller of the host address. In a first level of bootstrapping, the controller instructs the host to download a maintenance operating system. The host responds by downloading and installing a maintenance operating system, enabling further bootstrapping. The persistent memory may further have security data, such as a public key, that allows the host computing system to securely identify the source of the download instructions (and subsequent instructions) as originating from the controller. A second level of bootstrapping may accomplish the configuring of the host with a hypervisor and a host agent. A third level of bootstrapping may accomplish the provisioning of virtual machines on the host. | 12-26-2013 |
20130346988 | PARALLEL DATA COMPUTING OPTIMIZATION - The use of statistics collected during the parallel distributed execution of the tasks of a job may be used to optimize the performance of the task or similar recurring tasks. An execution plan for a job is initially generated, in which the execution plan includes tasks. Statistics regarding operations performed in the tasks are collected while the tasks are executed via parallel distributed execution. Another execution plan is then generated for another recurring job, in which the additional execution plan has at least one task in common with the execution plan for the job. The additional execution plan is subsequently optimized based at least on the statistics to produce an optimized execution plan. | 12-26-2013 |
20140082048 | NETWORK SERVICES PROVIDED IN CLOUD COMPUTING ENVIRONMENT - A cloud computing environment providing a network service for a client computing entity. The network service is not an application level service, but rather a service that operates at or below the network layer in the protocol stack. For instance, the network service might be a network endpoint service such as a network address service (such as DNS) or a dynamic network service (such as DHCP), or a network traffic service such as a firewall service or a secure tunneling service (such as VPN). The service might also provide a pipeline of network services for network level traffic to and from the client computing entity. The cloud environment uses policy to determine which of a plurality of communication channels to use when exchanging cloud service data for the network service. | 03-20-2014 |
20140195689 | SWAN: ACHIEVING HIGH UTILIZATION IN NETWORKS - Greater network utilization is implemented through dynamic network reconfiguration and allocation of network services and resources based on the data to be transferred and the consumer transferring it. A hierarchical system is utilized whereby requests from lower layers are aggregated before being provided to upper layers, and allocations received from upper layers are distributed to lower layers. To maximize network utilization, paths through the network are reconfigured by identifying specific types of packets that are to be flagged in a specific manner, and then by further identifying specific routing rules to be applied in the transmission of such packets. Network reconfiguration is performed on an incremental basis to avoid overloading a path, and capacity can be reserved along one or more paths to prevent such overloading. Background data is agnostic as to specific transmission times and is utilized to prevent overloading due to reconfiguration. | 07-10-2014 |
20140278047 | ENRICHING DRIVING EXPERIENCE WITH CLOUD ASSISTANCE - Described is a technology by which driver safety technology such as collision detection is implemented via mobile device (e.g., smartphone) sensors and a cloud service that processes data received from vehicles associated with the devices. Trajectory-related data is received at the cloud service and used to predict collisions between vehicles and/or lane departures of vehicles. To operate the service in real-time with low latency, also described is dividing driving areas into grids, e.g., based upon traffic density, having parallel grid servers each responsible for only vehicles in or approaching its own grid, and other parallel/distributed mechanisms of the cloud service. | 09-18-2014 |
20140347998 | ENSURING PREDICTABLE AND QUANTIFIABLE NETWORKING PERFORMANCE - The ensuring of predictable and quantifiable networking performance. Embodiments of the invention combine a congestion free network core with a hypervisor based (i.e., edge-based) throttling design to help insure quantitative and invariable subscription bandwidth rates. A lightweight shim layer in a hypervisor can adaptively throttle the rate of VM-to-VM traffic flow. A receiving hypervisor can detect congestion and communicate back to sending hypervisors that rates are to be regulated. In response, sending hypervisors can reduce transmission rate to mitigate congestion at the receiving hypervisor. In some embodiments, the principles are extended to any message processors communicating over a congestion free network. | 11-27-2014 |
20150262486 | ENRICHING DRIVING EXPERIENCE WITH CLOUD ASSISTANCE - Described is a technology by which driver safety technology such as collision detection is implemented via mobile device (e.g., smartphone) sensors and a cloud service that processes data received from vehicles associated with the devices. Trajectory-related data is received at the cloud service and used to predict collisions between vehicles and/or lane departures of vehicles. To operate the service in real-time with low latency, also described is dividing driving areas into grids, e.g., based upon traffic density, having parallel grid servers each responsible for only vehicles in or approaching its own grid, and other parallel/distributed mechanisms of the cloud service. | 09-17-2015 |
20150264135 | COMPUTING LONG-TERM SCHEDULES FOR DATA TRANSFERS OVER A WIDE AREA NETWORK - Various technologies pertaining to scheduling network traffic in a network are described. A request to transfer data from a first computing device to a second computing device includes data that identifies a volume of the data to be transferred and a deadline, where the data is to be transferred prior to the deadline. A long-term schedule is computed based upon the request, wherein the long-term schedule defines flow of traffic through the network over a relatively long time horizon. A short-term schedule is computed based upon the long-term schedule, where devices in the network are configured based upon the short-term schedule. | 09-17-2015 |
20150358198 | Dynamic Scheduling of Network Updates - The techniques and/or systems described herein are configured to determine a set of update operations to transition a network from an observed network state to a target network state and to generate an update dependency graph used to dynamically schedule the set of update operations based on constraint(s) defined to ensure reliability of the network during the transition. The techniques and/or systems dynamically schedule the set of update operations based on feedback. For example, the feedback may include an indication that a previously scheduled update operation has been delayed, has failed, or has been successfully completed. | 12-10-2015 |
20150358200 | PROACTIVE HANDLING OF NETWORK FAULTS - The techniques and/or systems described herein implement a fault handling service that is able to ensure that at least part of a network can avoid congestion (e.g., a link exceeding capacity) as long as a predetermined maximum number of faults is not exceeded. The fault handling service models different combinations of possible faults based on network topology and then computes an amount of traffic to be communicated via individual paths such that congestion is avoided as long as a number of actual faults that occur is less than or equal to the predetermined maximum number of faults. | 12-10-2015 |